---
title: "RedHill Biopharma shares jump on progress toward treating GLP-1 side effects"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/271534279.md"
description: "RedHill Biopharma Ltd. (NASDAQ:RDHL) shares surged 16.5% in premarket trading following the company's announcement of progress in developing RHB-102 (Bekinda), a treatment targeting gastrointestinal side effects associated with GLP-1/GIP weight-loss and diabetes medications. The biopharmaceutical firm is advancing RHB-102, a once-daily oral ondansetron formulation, through the U.S. regulatory process."
datetime: "2026-01-05T15:08:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271534279.md)
  - [en](https://longbridge.com/en/news/271534279.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271534279.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/271534279.md) | [English](https://longbridge.com/en/news/271534279.md)


# RedHill Biopharma shares jump on progress toward treating GLP-1 side effects

RedHill Biopharma Ltd. (NASDAQ:RDHL) shares climbed 16.5% in premarket trading on Monday after the company reported advances in the development of RHB-102 (Bekinda), a therapy aimed at addressing gastrointestinal side effects linked to widely used GLP-1/GIP weight-loss and diabetes drugs. The specialty biopharmaceutical group is progressing RHB-102—a once-daily oral formulation of ondansetron—through the U.S. Food \[…\]

### 相關股票

- [Redhill Biopharma (RDHL.US)](https://longbridge.com/zh-HK/quote/RDHL.US.md)

## 相關資訊與研究

- [RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects | RDHL Stock News](https://longbridge.com/zh-HK/news/271509313.md)
- [S&P Global Enhances Capital IQ Pro with Expanded Fixed Income, Biopharma and Private Markets Data Content and AI Capabilities](https://longbridge.com/zh-HK/news/278899470.md)
- [FDA Warns Novo Nordisk of Unreported Side Effects Tied to GLP-1 Patients](https://longbridge.com/zh-HK/news/278588381.md)
- [Pfizer Gains Chinese Approval for GLP-1 Weight Management Drug Enochlutide](https://longbridge.com/zh-HK/news/278064724.md)
- [Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.](https://longbridge.com/zh-HK/news/278546987.md)